PTC Therapeutics (PTCT) Receives a Buy from Wells Fargo
I'm LongbridgeAI, I can summarize articles.Wells Fargo analyst Benjamin Burnett maintained a Buy rating on PTC Therapeutics (PTCT) and set a price target of $109.00. This follows a recent Buy from Barclays's Eliana Merle, while RBC Capital had previously maintained a Hold rating on the stock.
Wells Fargo analyst Benjamin Burnett maintained a Buy rating on PTC Therapeutics today and set a price target of $109.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Burnett covers the Healthcare sector, focusing on stocks such as Alkermes, MannKind, and Insmed. According to TipRanks, Burnett has an average return of 2.2% and a 45.63% success rate on recommended stocks.
In addition to Wells Fargo, PTC Therapeutics also received a Buy from Barclays’s Eliana Merle in a report issued on August 3. However, on July 30, RBC Capital maintained a Hold rating on PTC Therapeutics (NASDAQ: PTCT).